Emerging Technologies seen driving global Electronics Manufacturing Services (EMS) industry’s 6.2% CAGR from 2015-2020. In recent years, SGX-listed EMS providers are diversifying their businesses away from traditional Technologies into emerging Technologies. Focus on emerging Technologies (e.g. Medical Technology, Life Sciences, Automotive Electronics) are now bearing fruit.
The STI has generated a 14.5% YTD dividend inclusive return, with Yangzijiang Shipbuilding Holdings (which joined the STI in September 2015) the strongest of the 30 STI constituents. The strongest STI Sector in the YTD has been Real Estate Management & Development – with Global Logistic Properties, City Developments, CapitaLand, UOL Group and Hongkong Land Holdings averaging 24.5% total returns.
Singapore’s Electronics cluster (27.4% of total manufacturing activity) demonstrates strong momentum with its 13th consecutive month of YoY output growth. SGX’s IT Sector is an outperformer in the YTD with total returns of 33.3%, above the STI’s +11.1% and the MSCI Asia ex-Japan IT Index’s +18.4%. Strong earnings outlook likely the key driver of IT Sector’s outperformance. Consensus expects 10 largest IT stocks* to grow earnings by 20% in 2017.
The MSCI Singapore Index (“SiMSCI Index”) ended yesterday at 358.3, which is a 18 month high and a 27% recovery from its February 2016 low. The SIMSCI Index has delivered a 14% YTD total return and been amongst the leading performers amongst key Asian indices. Half of the SiMSCI Index constituents have recently reported 1Q17 earnings. In addition, a slew of dividend distributions last week have seen the discount of the May SiMSCI Futures to the underlying SiMSCI Index narrow by 2.0 points.
SGX lists four Indian equity ETFs, three of which track the MSCI India Index, while the fourth tracks the Nifty 50 Index. They were among the top performing ETFs in the year-to-date, averaging a return of 16.0%. In the year thus far, Indian equity fund inflows have reached US$6.3 billion, second only to Taiwan in Asia. In terms of global fund flows, India was ranked 11th, above key Asian economies like South Korea, Malaysia and Indonesia, which are also experiencing net inflows in the year-to-date.
Information Technology (IT) was the best performing of Singapore’s Sectors in the 2017 YTD. The IT Sector generated a 4.9% capitalisation weighted total return in April, taking YTD gains to 33.3%. April was the third consecutive month the IT Sector was the best performing. The largest stock of Singapore IT Sector, Venture Corp reported 1Q17 results on Friday, with net profit up 36% YOY to S$48.6 million. Among the 10 largest stocks of Singapore’s IT Sector, Elec & Eltek International Co was the best YTD performer.
RHT generated total returns of 2.7% and 33.1% in the year-to-date and last 12 months, bringing its three-year total return to 80.5%. The trust currently trades at 1.1x price-to-book (P/B) ratio with 7.7% dividend yield. Parkway Life generated total returns of 11.0% and 11.1% in the year-to-date and last 12 months, bringing its three-year total return to 21.7%. The trust currently trades at 1.5x price-to-book (P/B) ratio with 5.1% dividend yield. First REIT generated total returns of 9.0% and 14.7% in the year-to-date and last 12 months, bringing its three-year total return to 43.6%. The trust currently trades at 1.3x price-to-book (P/B) ratio with 6.4% dividend yield.
Aoxin Q & M Dental Group Ltd (Aoxin), the first dental services and equipment provider in China, is scheduled to debut on Catalist tomorrow. Aoxin is one of the leading providers of private dental services/dental equipment and supplies in Liaoning Province, Northern China. SGX lists 20 Health Care Equipment and Services stocks with a combined market capitalisation of S$25.0 billion. Excluding secondary listings, these stocks averaged a total return of 17.3% in the YTD.
Despite being one of Singapore’s smaller healthcare sub-segments, the YTD total return of 7.3% generated by the six Pharmaceuticals stocks is almost double that of the overall SGX Healthcare Index. Against Asia-Pacific peers, Singapore Pharmaceuticals stocks trade at lower valuations of 13.9x PE and 1.2x PB, and generated higher total returns of 7.3% in the YTD (vs 2.2%) and 16.3% in the last one year (vs 7.7%).
The SGX Developed Asia ex Japan Quality Index is made up of 60 stocks listed across Singapore, Hong Kong and South Korea. With constituents maintaining comparatively strong financials, the Index has generated more resilient long term returns than relative benchmarks. Financial metrics for Quality Factors include net profit margins, return on equity & invested capital, the degree of financial leverage and accrued income.
These articles are provided by SGX My Gateway.
SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.
These articles are not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the “SGX Group Companies”) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.
